PARP1 and ovarian cancer: Moreover, similar results were seen in models of BRCA-mutant ovarian cancer, suggesting that inhibition of ATR potentiates the effects PARP inhibition in BRCA-deficient cells [77], thus the combination of PARP and ATR inhibition may have benefits in other HDR-deficient cancers.